by PEPID Newsroom | Mar 29, 2019 | Alerts
[elfsight_social_share_buttons id=”3″] Jatenzo, (testosterone undecanoate) has been given the FDA greenlight to be used as an oral capsule treatment for men with certain forms of hypogonadism. Jatenzo is the first treatment option for men with certain...
by PEPID Newsroom | Mar 28, 2019 | Alerts
Influenza activity, particularly caused by the A(H3N2) virus, remains elevated across the US. The CDC has released a health advisory, reminding clinicians to keep influenza top of mind when diagnosing patients with respiratory illness. The report contains several...
by PEPID Newsroom | Mar 25, 2019 | Alerts
Multiple states across the U.S. have reported hepatitis A outbreaks among people who use drugs and people experiencing homelessness. Since the initial awareness of the outbreak in 2016, there have been more than 15,000 cases with 57% in need of hospitalizations, and...
by PEPID Newsroom | Mar 21, 2019 | Alerts
The FDA approved the Optimizer Smart system for patients with chronic, moderate-to-severe heart failure who are not suited for treatment with other heart failure devices such as cardiac re-synchronization therapy to restore a normal heartbeat timing pattern. The...
by PEPID Newsroom | Mar 19, 2019 | Alerts
Tuesday, March 19, the FDA approved Zulresso (brexanolone) injection for intravenous (IV) use to treat post-partum depression (PPD) in adult women. No other drug before now has been approved to specifically treat PPD. Zulresso will be available through Risk Evaluation...
